276 related articles for article (PubMed ID: 7533183)
21. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro.
Gajewski TF; Renauld JC; Van Pel A; Boon T
J Immunol; 1995 Jun; 154(11):5637-48. PubMed ID: 7538528
[TBL] [Abstract][Full Text] [Related]
22. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
Leong C; Marley J; Loh S; Robinson B; Garlepp M
Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
[TBL] [Abstract][Full Text] [Related]
23. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T
Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119
[TBL] [Abstract][Full Text] [Related]
24. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma.
Yeh KY; Pulaski BA; Woods ML; McAdam AJ; Gaspari AA; Frelinger JG; Lord EM
Cell Immunol; 1995 Oct; 165(2):217-24. PubMed ID: 7553886
[TBL] [Abstract][Full Text] [Related]
25. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
26. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.
Zheng P; Wu Y; Guo Y; Lee C; Liu Y
Proc Natl Acad Sci U S A; 1998 May; 95(11):6284-9. PubMed ID: 9600957
[TBL] [Abstract][Full Text] [Related]
27. Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection.
Elloso MM; Scott P
J Immunol; 1999 Jun; 162(11):6708-15. PubMed ID: 10352289
[TBL] [Abstract][Full Text] [Related]
28. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
[TBL] [Abstract][Full Text] [Related]
29. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
30. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes.
Yang G; Mizuno MT; Hellström KE; Chen L
J Immunol; 1997 Jan; 158(2):851-8. PubMed ID: 8993003
[TBL] [Abstract][Full Text] [Related]
31. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses.
Roy M; Aruffo A; Ledbetter J; Linsley P; Kehry M; Noelle R
Eur J Immunol; 1995 Feb; 25(2):596-603. PubMed ID: 7533092
[TBL] [Abstract][Full Text] [Related]
32. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases.
Matsui T; Kurokawa M; Kobata T; Oki S; Azuma M; Tohma S; Inoue T; Yamamoto K; Nishioka K; Kato T
J Immunol; 1999 Apr; 162(7):4328-35. PubMed ID: 10201965
[TBL] [Abstract][Full Text] [Related]
33. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
34. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.
Chen L; McGowan P; Ashe S; Johnston J; Li Y; Hellström I; Hellström KE
J Exp Med; 1994 Feb; 179(2):523-32. PubMed ID: 7507508
[TBL] [Abstract][Full Text] [Related]
35. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation.
Yang G; Hellström KE; Mizuno MT; Chen L
J Immunol; 1995 Oct; 155(8):3897-903. PubMed ID: 7561096
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen.
Tsuji T; Hamajima K; Ishii N; Aoki I; Fukushima J; Xin KQ; Kawamoto S; Sasaki S; Matsunaga K; Ishigatsubo Y; Tani K; Okubo T; Okuda K
Eur J Immunol; 1997 Mar; 27(3):782-7. PubMed ID: 9079822
[TBL] [Abstract][Full Text] [Related]
37. Protective immunity induced by B7/CD28-costimulated gamma delta T cells to the EL-4 lymphoma in allogenic athymic mice.
Li Y; Newby SA; Johnston JV; Hellström KE; Chen L
J Immunol; 1995 Dec; 155(12):5705-10. PubMed ID: 7499857
[TBL] [Abstract][Full Text] [Related]
38. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4.
Kearney ER; Walunas TL; Karr RW; Morton PA; Loh DY; Bluestone JA; Jenkins MK
J Immunol; 1995 Aug; 155(3):1032-6. PubMed ID: 7543510
[TBL] [Abstract][Full Text] [Related]
39. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
40. Immunogene therapy against mouse leukemia using B7 molecules.
Takahashi T; Hirano N; Takahashi T; Chiba S; Yazaki Y; Hirai H
Cancer Gene Ther; 2000 Jan; 7(1):144-50. PubMed ID: 10678367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
